Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 sept. 2013 09h22 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Completes Enrollment in Phase 3 VALOR Trial of Vosaroxin in AML

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that enrollment in the company's pivotal, Phase 3 VALOR trial of vosaroxin...
19 sept. 2013 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will...
04 sept. 2013 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at the 2013 Stifel Nicolaus Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will...
07 août 2013 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at the 2013 Wedbush Life Sciences Management Access Conference

SOUTH SAN FRANCISCO, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and...
29 juil. 2013 16h01 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports Second Quarter Financial Results and Recent Highlights

VALOR Enrollment Exceeds 675 Patients Cardiff University-Sponsored LI-1 Trial Monotherapy Treatment Arm Evaluated by DMEC Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in...
13 juin 2013 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial With no Change to Study Conduct

SOUTH SAN FRANCISCO, Calif., June 13, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR...
12 juin 2013 14h24 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at the Wells Fargo 2013 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 12, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and...
11 juin 2013 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Appoints Steve Carchedi to Board of Directors

SOUTH SAN FRANCISCO, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Steve Carchedi has been appointed to the Sunesis Board of Directors,...
30 mai 2013 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Vosaroxin Review Published in Expert Opinion on Pharmacotherapy

SOUTH SAN FRANCISCO, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in Expert Opinion on Pharmacotherapy...
10 mai 2013 15h29 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Dan...

Page précédente